Werewolf Therapeutics, Inc.
NASDAQ:HOWLBiotechnology
+$0.06 today
- Market cap
- $50.06M
- Beta
- 0.29
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.71
Volume 1.85M
Average 5.09M
HOWL Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Werewolf Therapeutics, Inc.NASDAQ: HOWL
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $2.45M rose 503.9% year over year, ahead of the +111.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 516.1% from the prior quarter. Over 3 fiscal years it compounded at +14.0% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +503.9% holds above the trailing-twelve-month pace of +111.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.63M USD
- Year-over-year change
- -9.9%
- 4-year CAGR
- +65.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.63M | -9.9% |
| FY2024 | 2024-12-31 | 1.81M | +2.8% |
| FY2023 | 2023-12-31 | 1.76M | +59.8% |
| FY2022 | 2022-12-31 | 1.1M | +411.1% |
| FY2021 | 2021-12-31 | 216K | — |
Depreciation & Amortization vs competitors
How HOWL compares with its peers on the latest reported figures
- HOWL's LTM Jun 2026 depreciation & amortization of $3.65M is the 2nd highest of the 8 companies compared; the peer median is $306K.
- Its year-over-year change of +111.3% is the 3rd highest of 8, against a peer median of +10.5%.
- Depreciation & amortization amounts to 17.4% of revenue for HOWL, versus a peer median of 13.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.04M | -7.0% | +8.4% | — | |
| LTM Jun 2026 | $3.65M | +111.3% | +14.0% | 17.4% | |
| LTM Mar 2026 | $3.01M | +10.5% | +24.4% | 9.2% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $487.33K | +42.9% | +666.9% | — |
| LTM Mar 2026 | $306K | +6020.0% | +229.4% | 13.3% | |
| LTM Mar 2026 | $267K | +621.6% | -34.3% | — | |
| LTM Mar 2026 | $119.64K | +3.7% | -17.0% | 35.9% | |
| LTM Mar 2026 | $108K | -98.9% | -85.2% | — | |
| Peer median (excluding HOWL) | $306K | +10.5% | +8.4% | 13.3% | |
Competitors are the stored peer set for HOWL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 16.4M | 19.94M | 1.89M | 0 |
| Cost of Revenue | 0 | 2.51M | 1.76M | 1.81M | 1.63M |
| Gross Profit | 0 | 13.89M | 18.18M | 71K | (1.63M) |
| Gross Margin | — | 84.7% | 91.2% | 3.8% | — |
| Research & Development | 35.27M | 53.76M | 41.78M | 56.43M | 44.83M |
| Selling, General & Admin | 14.82M | 21.5M | 18.67M | 19.05M | 15.85M |
| Operating Expenses | 50.09M | 69.95M | 58.68M | 73.67M | 59.04M |
| Depreciation & Amortization | 216K | 1.1M | 1.76M | 1.81M | 1.63M |
| EBITDA | (49.77M) | (52.71M) | (32.47M) | (64.05M) | (53.91M) |
| EBITDA Margin | — | -321.4% | -162.8% | -3397.6% | — |
| Operating Income | (50.09M) | (56.06M) | (40.5M) | (73.59M) | (60.68M) |
| Operating Margin | — | -341.8% | -203.1% | -3904.2% | — |
| Interest Income | 104K | 1.91M | 7.42M | 6.67M | 3.11M |
| Interest Expense | 0 | 0 | 3.14M | 4.66M | 5.27M |
| Other Income / Expenses | 104K | 2.25M | 3.14M | 3.08M | (145K) |
| Income Before Tax | (49.98M) | (53.81M) | (37.37M) | (70.52M) | (60.82M) |
| Pre-Tax Margin | — | -328.1% | -187.4% | -3740.8% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (49.98M) | (53.81M) | (37.37M) | (70.52M) | (60.82M) |
| Net Margin | — | -328.1% | -187.4% | -3740.8% | — |
| EPS (Basic) | (10.94) | (1.86) | (1.05) | (1.63) | (1.32) |
| EPS (Diluted) | (10.94) | (1.86) | (1.05) | (1.63) | (1.33) |
| Weighted Avg Shares | 18.46M | 28.86M | 35.65M | 43.33M | 46.02M |
| Weighted Avg Shares (Diluted) | 18.46M | 28.86M | 35.65M | 43.86M | 46.81M |
Werewolf Therapeutics, Inc.
NASDAQ:HOWL
Intrinsic Alpha fair value
Locked
Current Price
$1.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.